BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:The pulmonary fibrosis field is entering a pivotal moment. Boe
 hringer Ingelheim’s positive Phase 3 trials for nerandomilast\, poised to
  be the first new approval in over a decade\, have injected long-awaited 
 momentum into the space. PureTech Health\, Endeavor BioMedicines\, Insili
 co Medicine\, Bristol Myers Squibb\, and United Therapeutics are rapidly 
 advancing through mid- to late-stage trials\, signaling a renewed era of 
 therapeutic possibility. Yet 2025 has also brought setbacks\, including P
 liant’s discontinuation of the BEACON-IPF study for bexotegrast due to sa
 fety concerns\, underscoring the complexity of treating this disease.\n\n
 If ever there was a year to invest in this space\, it’s now. This August\
 , meet your global community\, spanning discovery\, preclinical\, transla
 tional\, and clinical development\, at the only industry-focused summit d
 edicated to pulmonary fibrosis. Gain the full spectrum of insight needed 
 to bring better drugs to patients\, faster.\n\nView the full agenda here:
  https://ter.li/7e36ja\n\n&nbsp\;\n\nTime: 9:00 AM - 5:00 PM\n
DTEND:20250821T170000
DTSTAMP:20260512T223116Z
DTSTART:20250819T090000
LOCATION:Hilton Boston Park Plaza\, 50 Park Plaza\, Boston\, Massachusetts
 \, 02116\,
SEQUENCE:0
SUMMARY:The pulmonary fibrosis field is entering a pivotal moment. Boehrin
 ger Ingelheim’s positive Phase 3 trials for nerandomilast\, poised to be 
 the first...
UID:2bd85fdb-8f9e-4031-ab21-608d40e6a17e
END:VEVENT
END:VCALENDAR